{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:19:26Z","timestamp":1648559966319},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11886-000-0075-5","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T10:54:06Z","timestamp":1180695246000},"page":"244-251","source":"Crossref","is-referenced-by-count":2,"title":["Current management of patients with pulmonary hypertension and right ventricular insufficiency"],"prefix":"10.1007","volume":"2","author":[{"given":"Shelley R.","family":"Hankins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn M.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"75_CR1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1161\/01.CIR.90.6.2780","volume":"90","author":"E Loh","year":"1994","unstructured":"Loh E, Stamler JS, Hare JM, et al.: Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994, 90:2780\u20132785.","journal-title":"Circulation"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1161\/01.CIR.95.12.2603","volume":"95","author":"J Morse","year":"1997","unstructured":"Morse J, Jones AC, Barst RJ, et al.: Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-32. Circulation 1997, 95:2603\u20132606.","journal-title":"Circulation"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/ng0397-277","volume":"15","author":"WC Nichols","year":"1997","unstructured":"Nichols WC, Koller DL, Slovis B, et al.: Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997, 15:277\u2013280.","journal-title":"Nat Genet"},{"key":"75_CR4","unstructured":"Rich S: Primary Pulmonary Hypertension: Executive Summary from the World Symposium-Primary Pulmonary Hypertension 1998. Available from the World Health Organization via the Internet. http:\/\/www.who.int\/ncd\/dvd\/pph.html 1998. Excellent review of classification, pathology, pathophysiology, genetics and treatment by leaders of the field, although there is no bibliography."},{"key":"75_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0008-6363(99)00230-8","volume":"44","author":"C Veyssier-Belot","year":"1999","unstructured":"Veyssier-Belot C, Cacoub P: Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 1999, 44:274\u2013282. Reasonable review of endothelial and smooth muscle-related pulmonary vasculopathy.","journal-title":"Cardiovasc Res"},{"key":"75_CR6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","volume":"80","author":"G Pietra","year":"1989","unstructured":"Pietra G, Edwards W, Kay J, et al.: Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, primary pulmonary hypertension Registry. Circulation 1989, 80:1198\u20131206.","journal-title":"Circulation"},{"key":"75_CR7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343\u2013349.","journal-title":"Ann Intern Med"},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI111499","volume":"74","author":"M McGoon","year":"1984","unstructured":"McGoon M, Vanhoutte P: Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984, 74:823\u2013833.","journal-title":"J Clin Invest"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","volume":"159","author":"RM Tuder","year":"1999","unstructured":"Tuder RM, Cool CD, Geraci MW, et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925\u20131932. Evidence that PGI2-synthase is decreased in PPH, HIV-associated, and portal-pulmonary hypertension.","journal-title":"Am J Respir Crit Care Med"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH, et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70\u201375.","journal-title":"N Engl J Med"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1172\/JCI5911","volume":"103","author":"MW Geraci","year":"1999","unstructured":"Geraci MW, Gao B, Shepard DC, et al.: Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999, 103:1509\u20131515. Transgenic mice with overespression of prostacyclin synthase protected against the development of hypoxia-mediated pulmonary hypertension begin to show some causality.","journal-title":"J Clin Invest"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D: Reduced expression of nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214\u2013221.","journal-title":"N Engl J Med"},{"key":"75_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0147-9563(97)90087-X","volume":"26","author":"A Angerio","year":"1997","unstructured":"Angerio A, Kot P: Endothelin-1: Possible implications in pulmonary vascular disease. Heart Lung 1997, 26:299\u2013304.","journal-title":"Heart Lung"},{"key":"75_CR14","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.84.6.2280","volume":"84","author":"M Yoshibayashi","year":"1991","unstructured":"Yoshibayashi M, Nichioka K, Nakao K, et al.: Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Circulation 1991, 84:2280\u20132295.","journal-title":"Circulation"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0008-6363(96)00219-2","volume":"33","author":"D Kiely","year":"1997","unstructured":"Kiely D, Cargill R, Struthers A, Lipworth B: Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997, 33:378\u2013386.","journal-title":"Cardiovasc Res"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-9149(98)00296-3","volume":"82","author":"M Ghada","year":"1998","unstructured":"Ghada M, Chester A, Gibbs S, et al.: Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol 1998, 82:254\u2013255.","journal-title":"Am J Cardiol"},{"key":"75_CR17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","volume":"26","author":"M Nootens","year":"1995","unstructured":"Nootens M, Kaufmann E, Rector T, et al.: Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. JACC 1995, 26:1581\u20131585.","journal-title":"JACC"},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.1996.tb32580.x","volume":"796","author":"N Voelkel","year":"1996","unstructured":"Voelkel N, Hoeper M, Maloney J, Tuder R: Vascular endothelial growth factor in pulmonary hypertension. Ann NY Acad Sci 1996, 796:186\u2013193.","journal-title":"Ann NY Acad Sci"},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1172\/JCI448","volume":"101","author":"SD Lee","year":"1998","unstructured":"Lee SD, Shroyer KR, Markham NE, et al.: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998, 101:1001\u20131011.","journal-title":"J Clin Invest"},{"key":"75_CR20","first-page":"275","volume":"144","author":"RM Tuder","year":"1994","unstructured":"Tuder RM, Groves B, Badesch DB, Voelkel NF: Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275\u2013278.","journal-title":"Am J Pathol"},{"key":"75_CR21","first-page":"I","volume":"1996","author":"XJ Yuan","year":"1996","unstructured":"Yuan XJ, Aldinger A, Orens J, et al.: Dysfunctional voltage-gated potassium channels in the pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1996, 1996:I-49.","journal-title":"Circulation"},{"key":"75_CR22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1442-200X.1995.tb03400.x","volume":"37","author":"M Rabinovitch","year":"1995","unstructured":"Rabinovitch M, Elastic and cell matrix interactions in the pathophysiology of vascular disease. Acta Paediatr Jpn 1995, 37:657\u2013666.","journal-title":"Acta Paediatr Jpn"},{"key":"75_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/ajrccm.150.4.7921465","volume":"150","author":"K Huber","year":"1994","unstructured":"Huber K, Beckmann R, Frank H, et al.: Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994, 150:929\u2013933.","journal-title":"Am J Respir Crit Care Med"},{"key":"75_CR24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.77.5.614","volume":"77","author":"CA Wagenvoort","year":"1980","unstructured":"Wagenvoort CA: Lung biopsy specimens in the evaluation of pulmonary vasuclar disease. Chest 1980, 77:614\u2013625.","journal-title":"Chest"},{"key":"75_CR25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.82.3.841","volume":"82","author":"PR Eisenberg","year":"1990","unstructured":"Eisenberg PR, Lucore C, Kaufman L, et al.: Fibrinopeptide A levles indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990, 82:841\u2013847.","journal-title":"Circulation"},{"key":"75_CR26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/ajrccm.150.4.7921465","volume":"150","author":"M Humbert","year":"1994","unstructured":"Humbert M, Monti G, Brenot F, et al.: Serum IL-1, IL-6 and TNF-alpha in primary pulmonary hypertension. Am J Respir Crit Care Med 1994, 150:929\u2013933.","journal-title":"Am J Respir Crit Care Med"},{"key":"75_CR27","first-page":"A746","volume":"149","author":"CH Welsch","year":"1994","unstructured":"Welsch CH, Marlar RA, Hassell KL: Coagulation activation, fibrinolysis and severity of pulmonary hypertension. Am J Respir Crit Care Med 1994, 149:A746.","journal-title":"Am J Respir Crit Care Med"},{"key":"75_CR28","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/01.CIR.94.9.2216","volume":"94","author":"E Weir","year":"1996","unstructured":"Weir E, Reeve H, Huang J, et al.: Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996, 94:2216\u20132220.","journal-title":"Circulation"},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","volume":"99","author":"RJ Barst","year":"1999","unstructured":"Barst RJ, Maislin G, Fishman AP: Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999, 99:1197\u2013208. Longer term follow-up of efficacy of vasodilators in children with PPH.","journal-title":"Circulation"},{"key":"75_CR30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","volume":"327","author":"S Rich","year":"1992","unstructured":"Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N Engl J Med 1992, 327:76\u201381.","journal-title":"N Engl J Med"},{"key":"75_CR31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.94.3.346","volume":"94","author":"H Figulla","year":"1996","unstructured":"Figulla H, Gietzen F, Zeymer U, et al.: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the diltiazem in dilated cardiomyopathy trial (DiDi). Circulation 1996, 94:346\u2013352.","journal-title":"Circulation"},{"key":"75_CR32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","volume":"335","author":"M Packer","year":"1996","unstructured":"Packer M, O\u2019Connor C, Ghali J, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure (PRAISE). N Engl J Med 1996, 335:1107\u20131114.","journal-title":"N Engl J Med"},{"key":"75_CR33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1378\/chest.99.3.715","volume":"99","author":"J Klinger","year":"1991","unstructured":"Klinger J, Hill N: Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest 1991, 99:715\u2013723.","journal-title":"Chest"},{"key":"75_CR34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]. N Engl J Med 1996, 334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"75_CR35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","volume":"30","author":"SM Shapiro","year":"1997","unstructured":"Shapiro SM, Oudiz RJ, Cao T, et al.: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997, 30:343\u2013349.","journal-title":"J Am Coll Cardiol"},{"key":"75_CR36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.95.6.1479","volume":"95","author":"AL Hinderliter","year":"1997","unstructured":"Hinderliter AL, Willis PW 4th, Barst RJ, et al.: Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group [see comments]. Circulation 1997, 95:1479\u20131486.","journal-title":"Circulation"},{"key":"75_CR37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","volume":"121","author":"RJ Barst","year":"1994","unstructured":"Barst RJ, Rubin LJ, McGoon MD, et al.: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin [see comments]. Ann Intern Med 1994, 121:409\u2013415.","journal-title":"Ann Intern Med"},{"key":"75_CR38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","volume":"338","author":"VV McLaughlin","year":"1998","unstructured":"McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [see comments]. N Engl J Med 1998, 338:273\u2013277. Acute nonresponders to vasodilators benefit from long-term use of PGI2. Acute hemodynamics do not predict long-term responsiveness and suggests conceptual vascular remodeling.","journal-title":"N Engl J Med"},{"key":"75_CR39","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH: A comparison of continuous intravenous epoprostenol with conventional therapy for pulmonary hypertension secondary to the scleroderma spectrum of disease. Ann Intern Med 2000, in press. Efficacy of PGI2 in a secondary form of pulmonary hypertension."},{"key":"75_CR40","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","volume":"99","author":"EB Rosenzweig","year":"1999","unstructured":"Rosenzweig EB, Kerstein D, Barst RJ: Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999, 99:1858\u20131865. Efficacy of PGI2 in a secondary form of pulmonary hypertension.","journal-title":"Circulation"},{"key":"75_CR41","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","volume":"34","author":"N Nagaya","year":"1999","unstructured":"Nagaya N, Uematsu M, Okano Y, et al.: Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999, 34:1188\u20131192.","journal-title":"J Am Coll Cardiol"},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0002-9149(98)00214-8","volume":"81","author":"T Koelling","year":"1998","unstructured":"Koelling T, Kirmse M, Di Salvo T, et al.: Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998, 81:1494\u20131497.","journal-title":"Am J Cardiol"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","volume":"134","author":"R Califf","year":"1997","unstructured":"Califf R, Adams K, McKenna W, et al.: A randomized controlled trial of epoprostenol therapy in severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997, 134:44\u201354.","journal-title":"Am Heart J"},{"key":"75_CR44","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.114.3.787","volume":"114","author":"S Rich","year":"1998","unstructured":"Rich S, Seidlitz M, Dodin E, et al.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998, 114:787\u2013792.","journal-title":"Chest"},{"key":"75_CR45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","volume":"112","author":"H Frank","year":"1997","unstructured":"Frank H, Mlczoch J, Huber K, et al.: Effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997, 112:714\u2013721.","journal-title":"Chest"},{"key":"75_CR46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9149(97)00370-6","volume":"80","author":"S Rich","year":"1997","unstructured":"Rich S, Dodin E, McLaughlin VV: Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997, 80:369\u2013371.","journal-title":"Am J Cardiol"},{"key":"75_CR47","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1161\/01.CIR.91.7.2028","volume":"91","author":"D Kerstein","year":"1995","unstructured":"Kerstein D, Levy PS, Hsu DT, et al.: Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995, 91:2028\u20132035.","journal-title":"Circulation"},{"key":"75_CR48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0002-9149(99)00416-6","volume":"84","author":"A Rothman","year":"1999","unstructured":"Rothman A, Sklansky MS, Lucas VW, et al.: Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999, 84:682\u2013686.","journal-title":"Am J Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-000-0075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-000-0075-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-000-0075-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:55:47Z","timestamp":1559433347000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-000-0075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s11886-000-0075-5","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}